
Results
2
Companies which are more than 50% undervalued based on analyst price target.
2 companies
Oryzon Genomics
Market Cap: €236.4m
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.
ORY
€2.88
7D
-2.6%
1Y
10.3%
Labiana Health
Market Cap: €52.7m
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally.
LAB
€6.30
7D
-0.8%
1Y
70.3%